These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7987974)

  • 1. Human metabolism of the experimental cancer therapeutic agent d-limonene.
    Crowell PL; Elson CE; Bailey HH; Elegbede A; Haag JD; Gould MN
    Cancer Chemother Pharmacol; 1994; 35(1):31-7. PubMed ID: 7987974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of perillic acid in humans after a single dose administration of a citrus preparation rich in d-limonene content.
    Chow HH; Salazar D; Hakim IA
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1472-6. PubMed ID: 12433729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
    Vigushin DM; Poon GK; Boddy A; English J; Halbert GW; Pagonis C; Jarman M; Coombes RC
    Cancer Chemother Pharmacol; 1998; 42(2):111-7. PubMed ID: 9654110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry.
    Poon GK; Vigushin D; Griggs LJ; Rowlands MG; Coombes RC; Jarman M
    Drug Metab Dispos; 1996 May; 24(5):565-71. PubMed ID: 8723738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R-Limonene metabolism in humans and metabolite kinetics after oral administration.
    Schmidt L; Göen T
    Arch Toxicol; 2017 Mar; 91(3):1175-1185. PubMed ID: 27325307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth.
    Crowell PL; Lin S; Vedejs E; Gould MN
    Cancer Chemother Pharmacol; 1992; 31(3):205-12. PubMed ID: 1464157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of protein prenylation by metabolites of limonene.
    Hardcastle IR; Rowlands MG; Barber AM; Grimshaw RM; Mohan MK; Nutley BP; Jarman M
    Biochem Pharmacol; 1999 Apr; 57(7):801-9. PubMed ID: 10075086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
    Phillips LR; Malspeis L; Supko JG
    Drug Metab Dispos; 1995 Jul; 23(7):676-80. PubMed ID: 7587953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gas chromatographic-mass spectrometric analysis of d-limonene in human plasma.
    Wang S; Chen Y; Gao Z; Xiong M; Zhong Z; Ye L
    J Pharm Biomed Anal; 2007 Sep; 44(5):1095-9. PubMed ID: 17540528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of d-limonene in the rat by GC-MS assay.
    Chen H; Chan KK; Budd T
    J Pharm Biomed Anal; 1998 Aug; 17(4-5):631-40. PubMed ID: 9682146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence evaluation of two D-limonene capsule formulations in healthy Chinese volunteers.
    Liu T; Guo Y; Gao Z; Chen Z; Jiang X
    Pharmazie; 2008 Oct; 63(10):718-20. PubMed ID: 18972832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma.
    Zhang Z; Chen H; Chan KK; Budd T; Ganapathi R
    J Chromatogr B Biomed Sci Appl; 1999 May; 728(1):85-95. PubMed ID: 10379660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
    Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
    Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. d-limonene exposure to humans by inhalation: uptake, distribution, elimination, and effects on the pulmonary function.
    Falk-Filipsson A; Löf A; Hagberg M; Hjelm EW; Wang Z
    J Toxicol Environ Health; 1993 Jan; 38(1):77-88. PubMed ID: 8421324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fate of dermally applied [14C]d-limonene in rats and humans.
    Api AM; Ritacco G; Hawkins DR
    Int J Toxicol; 2013; 32(2):130-5. PubMed ID: 23493903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and immune responses resulting from oral administration of D-limonene in rats.
    Hamada M; Uezu K; Matsushita J; Yamamoto S; Kishino Y
    J Nutr Sci Vitaminol (Tokyo); 2002 Apr; 48(2):155-60. PubMed ID: 12171437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer.
    Miller JA; Lang JE; Ley M; Nagle R; Hsu CH; Thompson PA; Cordova C; Waer A; Chow HH
    Cancer Prev Res (Phila); 2013 Jun; 6(6):577-84. PubMed ID: 23554130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a gas chromatograph with parallel radioactivity and mass spectrometric detection. Application to the identification of the major metabolite of d-limonene associated with alpha 2u-globulin.
    Rodriguez PA; Takigiku R; Lehman-McKeeman LD; Fey ML; Eddy CL; Caudill D
    J Chromatogr; 1991 Feb; 563(2):271-82. PubMed ID: 1711535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anxiolytic-like activity and GC-MS analysis of (R)-(+)-limonene fragrance, a natural compound found in foods and plants.
    Lima NG; De Sousa DP; Pimenta FC; Alves MF; De Souza FS; Macedo RO; Cardoso RB; de Morais LC; Melo Diniz Mde F; de Almeida RN
    Pharmacol Biochem Behav; 2013 Jan; 103(3):450-4. PubMed ID: 22995322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-Limonene modulates T lymphocyte activity and viability.
    Lappas CM; Lappas NT
    Cell Immunol; 2012 Sep; 279(1):30-41. PubMed ID: 23059811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.